Literature DB >> 14662110

Biologic therapies for dyslipidemia.

Michael H Davidson1.   

Abstract

Biologic therapies involve the utilization of proteins, DNA, antibodies, or other substances derived or synthesized from living tissue for therapeutic effects. There are several biologic therapies in clinical development for the prevention and treatment of atherosclerosis. The most advanced in human trials are apolipoprotein mimetics, which include apolipoprotein A-1 Milano and phospholipid complexes. Infusions of these apolipoprotein mimetics have been demonstrated to reduce atherosclerotic development in both animal models and humans. Autoimmunization to create neutralizing antibodies to cholesteryl ester transfer protein is also in human trials. Gene therapies to reduce low-density lipoproteins and increase high-density lipoproteins are on the horizon, but the ability to safely prolong gene expression in humans will require the development of novel vectors.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14662110     DOI： 10.1007/s11883-004-0118-2

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN： 1523-3804            Impact factor:   5.113


  29 in total

1.  Increased expression of apolipoprotein E in transgenic rabbits results in reduced levels of very low density lipoproteins and an accumulation of low density lipoproteins in plasma.

Authors:  J Fan; Z S Ji; Y Huang; H de Silva; D Sanan; R W Mahley; T L Innerarity; J M Taylor
Journal:  J Clin Invest       Date:  1998-05-15       Impact factor: 14.808

2.  Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity.

Authors:  K Hirano; S Yamashita; N Nakajima; T Arai; T Maruyama; Y Yoshida; M Ishigami; N Sakai; K Kameda-Takemura; Y Matsuzawa
Journal:  Arterioscler Thromb Vasc Biol       Date:  1997-06       Impact factor: 8.311

3.  Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Potential reverse cholesterol transport in humans.

Authors:  M Eriksson; L A Carlson; T A Miettinen; B Angelin
Journal:  Circulation       Date:  1999-08-10       Impact factor: 29.690

4.  Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis.

Authors:  C W Rittershaus; D P Miller; L J Thomas; M D Picard; C M Honan; C D Emmett; C L Pettey; H Adari; R A Hammond; D T Beattie; A D Callow; H C Marsh; U S Ryan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-09       Impact factor: 8.311

5.  Cationic domain 141-150 of apoE covalently linked to a class A amphipathic helix enhances atherogenic lipoprotein metabolism in vitro and in vivo.

Authors:  G Datta; D W Garber; B H Chung; M Chaddha; N Dashti; W A Bradley; S H Gianturco; G M Anantharamaiah
Journal:  J Lipid Res       Date:  2001-06       Impact factor: 5.922

6.  Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease.

Authors:  M Cavazzana-Calvo; S Hacein-Bey; G de Saint Basile; F Gross; E Yvon; P Nusbaum; F Selz; C Hue; S Certain; J L Casanova; P Bousso; F L Deist; A Fischer
Journal:  Science       Date:  2000-04-28       Impact factor: 47.728

Review 7.  An overview of reverse cholesterol transport.

Authors:  A R Tall
Journal:  Eur Heart J       Date:  1998-02       Impact factor: 29.983

8.  High-dose recombinant apolipoprotein A-I(milano) mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein e-deficient mice. Potential implications for acute plaque stabilization.

Authors:  P K Shah; J Yano; O Reyes; K Y Chyu; S Kaul; C L Bisgaier; S Drake; B Cercek
Journal:  Circulation       Date:  2001-06-26       Impact factor: 29.690

Review 9.  Reverse cholesterol transport in man: promotion of fecal steroid excretion by infusion of reconstituted HDL.

Authors:  Bo Angelin; Paolo Parini; Mats Eriksson
Journal:  Atheroscler Suppl       Date:  2002-12       Impact factor: 3.235

10.  A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia.

Authors:  M Grossman; D J Rader; D W Muller; D M Kolansky; K Kozarsky; B J Clark; E A Stein; P J Lupien; H B Brewer; S E Raper
Journal:  Nat Med       Date:  1995-11       Impact factor: 53.440
View more
  3 in total

1.  Newer antiatherosclerosis treatment strategies.

Authors:  Amitesh Aggarwal; Safal Singh
Journal:  Heart Asia       Date:  2011-01-01

2.  Anti-inflammatory peptides grab on to the whiskers of atherogenic oxidized lipids.

Authors:  Raquel F Epand; Vinod K Mishra; Mayakonda N Palgunachari; G M Anantharamaiah; Richard M Epand
Journal:  Biochim Biophys Acta       Date:  2009-06-25

Review 3.  Isolated low high density lipoprotein-cholesterol (HDL-C): implications of global risk reduction. Case report and systematic scientific review.

Authors:  Melvin R Hayden; Suresh C Tyagi
Journal:  Cardiovasc Diabetol       Date:  2005-01-04       Impact factor: 9.951
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.